var title_f1_52_1856="HME selection device for mechanical ventilator";
var content_f1_52_1856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Heat and moisture exchange (HME) selection device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heat and moisture exchange (HME) selection device uses a rotating collar to allow switching from HME mode for heat and moisture exchange to AEROSOL mode without opening the ventilator circuit. In HME mode, the unit functions as a heat and moisture exchanger. In AEROSOL mode, the heat and moisture function is bypassed for administration of an aerosolized or MDI medication.",
"    <div class=\"footnotes\">",
"     HME: heat and moisture exchanger; MDI: metered dose inhaler.",
"    </div>",
"    <div class=\"reference\">",
"     Used with permission: Copyright &copy; 2012 Teleflex Incorporated.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1856=[""].join("\n");
var outline_f1_52_1856=null;
var title_f1_52_1857="Cystic bronchiectasis CT";
var content_f1_52_1857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Post-tuberculous bronchiectasis characterized by marked destruction of the right upper lobe with cylindrical and cystic bronchiectasis and cicatrization atelectasis. These findings explain the ipsilateral rotational shift of the mediastinum. Cylindrical and varicose bronchiectasis is present in the left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1857=[""].join("\n");
var outline_f1_52_1857=null;
var title_f1_52_1858="Technetium Tc-99m gluceptate: Drug information";
var content_f1_52_1858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m gluceptate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/52/42818?source=see_link\">",
"    see \"Technetium Tc-99m gluceptate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13206419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DRAXIMAGE&reg; Gluceptate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13206421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13206491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Brain imaging:",
"     </b>",
"     I.V. (based on 70 kg patient): 15-20 mCi (555-740 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal imaging:",
"     </b>",
"     I.V. (based on 70 kg patient): 10-15 mCi (370-555 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13253413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 4-6 hours following administration to decrease radiation exposure to the bladder.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13206440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluation of renal and brain perfusion",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13206506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Dermatologic: Dermal hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13206441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only  under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"     <b>",
"      Note:",
"     </b>",
"     Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Patients with renal disease may have delayed elimination, therefore decreasing quality of images.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 4-6 hours following administration to decrease radiation exposure to the bladder.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13206472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13206473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13206478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17916861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Technetium Tc 99m gluceptate is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16812 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1858=[""].join("\n");
var outline_f1_52_1858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206419\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206421\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206491\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13253413\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206440\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255274\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206506\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206441\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206472\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206473\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206478\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916861\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16812\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16812|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/52/42818?source=related_link\">",
"      Technetium Tc-99m gluceptate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_52_1859="HeartWare LVAD";
var content_f1_52_1859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    The HeartWare Ventricular Assist System",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the rotor is magnetically levitated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission. Copyright &copy; 2012 HeartWare, Inc.",
"     <a href=\"file://www.heartware.com\" target=\"_blank\">",
"      www.heartware.com",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1859=[""].join("\n");
var outline_f1_52_1859=null;
var title_f1_52_1860="Vertebral burst fracture of the lumbar spine";
var content_f1_52_1860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Vertebral burst fracture of the lumbar spine: Plain radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The x-rayx&nbsp;are from a 37-year-old female drug addict who jumped from a building in a suicide attempt. The plain x-rays in lateral projection (A) and AP projection (B) of the lumbar spine show a burst fracture of L1 characterized by loss of height and malposition of the L1 vertebral body with posterior retropulsion into the spinal canal (white arrow). The posterior elements are splayed as reflected in the widening of the pedicles (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Frymoyer JW, Wiesel SW, et al. The Adult and Pediatric Spine. Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1860=[""].join("\n");
var outline_f1_52_1860=null;
var title_f1_52_1861="Abatacept: Patient drug information";
var content_f1_52_1861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Abatacept: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     see \"Abatacept: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/6/44132?source=see_link\">",
"     see \"Abatacept: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2452297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Orencia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5663024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Orencia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to abatacept or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done. A hepatitis B infection may get worse during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had TB (tuberculosis) or have been close to someone who has TB, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need a TB (tuberculosis) test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3531402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Let shot sit out for 30 to 60 minutes to warm up before giving it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3302622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         SubQ:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11122 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1861=[""].join("\n");
var outline_f1_52_1861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2452297\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5663024\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021416\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021418\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021417\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021422\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021423\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021425\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021420\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021421\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021426\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021427\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=related_link\">",
"      Abatacept: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/6/44132?source=related_link\">",
"      Abatacept: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_52_1862="Topical tretinoin (topical all trans retinoic acid): Drug information";
var content_f1_52_1862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topical tretinoin (topical all trans retinoic acid): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/42/30372?source=see_link\">",
"    see \"Topical tretinoin (topical all trans retinoic acid): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43171?source=see_link\">",
"    see \"Topical tretinoin (topical all trans retinoic acid): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atralin&trade;;",
"     </li>",
"     <li>",
"      Avita&reg;;",
"     </li>",
"     <li>",
"      Refissa&reg;;",
"     </li>",
"     <li>",
"      Renova&reg;;",
"     </li>",
"     <li>",
"      Retin-A Micro&reg;;",
"     </li>",
"     <li>",
"      Retin-A&reg;;",
"     </li>",
"     <li>",
"      Tretin-X&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rejuva-A&reg;;",
"     </li>",
"     <li>",
"      Renova&reg;;",
"     </li>",
"     <li>",
"      Retin-A Micro&reg;;",
"     </li>",
"     <li>",
"      Retin-A&reg;;",
"     </li>",
"     <li>",
"      Retinova&reg;;",
"     </li>",
"     <li>",
"      Stieva-A;",
"     </li>",
"     <li>",
"      Vitamin A Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Retinoic Acid Derivative;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Topical: Begin therapy with a weaker formulation of tretinoin (0.025% cream, 0.04% microsphere gel, or 0.01% gel) and increase the concentration as tolerated; apply once daily to acne lesions before retiring or on alternate days; if stinging or irritation develop, decrease frequency of application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin:",
"     </b>",
"     Topical: Pea-sized amount of the 0.02% or 0.05% cream applied to entire face once daily in the evening",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F230501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43171?source=see_link\">",
"      see \"Topical tretinoin (topical all trans retinoic acid): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years: Acne vulgaris: Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of the 0.02% cream in patients 65-71 years of age showed similar improvement in fine wrinkles as seen in patients &lt;65 years. Safety and efficacy of the 0.02% cream have not been established in patients &gt;71 years of age. Safety and efficacy of the 0.05% cream have not been established in patients &gt;50 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.025% (20 g, 45 g); 0.05% (20 g, 40 g, 45 g, 60 g); 0.1% (20 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avita&reg;: 0.025% (20 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refissa&reg;: 0.05% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renova&reg;: 0.02% (40 g, 44 g, 60 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retin-A&reg;: 0.025% (20 g, 45 g); 0.05% (20 g, 45 g); 0.1% (20 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.025% (35 g) [kit includes cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.0375% (35 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.05% (35 g); 0.1% (35 g) [kit includes cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.01% (15 g, 45 g); 0.025% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atralin&trade;: 0.05% (45 g) [contains benzyl alcohol, fish collagen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avita&reg;: 0.025% (20 g, 45 g) [contains ethanol 83%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retin-A&reg;: 0.01% (15 g, 45 g); 0.025% (15 g, 45 g) [contains ethanol 90% w/w]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tretin-X&reg;: 0.01% (35 g); 0.025% (35 g) [contains ethanol 90% w/w; kit includes cleanser and moisturizer]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [microsphere gel]: 0.04% (20 g, 45 g, 50 g); 0.1% (20 g, 45 g, 50 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retin-A Micro&reg;: 0.04% (20 g, 45 g, 50 g); 0.1% (20 g, 45 g, 50 g) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin: Cream: Prior to application, gently wash face with a mild soap. Pat dry. Wait 20-30 minutes to apply cream. Avoid eyes, ears, nostrils, and mouth.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acne vulgaris; photodamaged skin; palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin as part of a comprehensive skin care and sun avoidance program",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F230504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some skin cancers",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tretinoin may be confused with ISOtretinoin, Tenormin&reg;, triamcinolone, trientine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Renova [U.S., Canada] may be confused with Remov brand name for nimesulide [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Excessive dryness, erythema, scaling of the skin, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperpigmentation or hypopigmentation, photosensitivity, initial acne flare-up",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Edema, blistering, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tretinoin or any component of the formulation; sunburn",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Use is associated with increased susceptibility/sensitivity to UV light; avoid sunlamps or excessive sunlight exposure. Daily sunscreen use and other protective measures recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Skin irritation: Treatment can increase skin sensitivity to weather extremes of wind or cold. Also, concomitant topical medications (eg, medicated or abrasive soaps, cleansers, or cosmetics with a strong drying effect) should be used with caution due to increased skin irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eczema: Use with caution in patients with eczema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cream 0.02% Do not use the 0.02% cream for longer than 52 weeks when using for palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cream 0.05% Do not use the 0.05% cream for longer than 48 weeks when using for palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gel: Flammable; do not expose to high temperatures or flame.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with abraded skin, sunburned skin, mucous membranes, eyes, mouth, angles of the nose. Not for use on moderate- to heavily-pigmented skin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F230486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Avoid excessive intake of vitamin A (cod liver oil, halibut fish oil).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization). Avoid excessive amounts of vitamin A supplements.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral tretinoin is teratogenic and fetotoxic in rats at doses 1000 and 500 times the topical human dose, respectively. Tretinoin does not appear to be teratogenic when used topically since it is rapidly metabolized by the skin; however, there are rare reports of fetal defects. Use for acne only if benefit to mother outweighs potential risk to fetus. During pregnancy, do not use for palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F230479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Avita External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (20 g): $101.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Refissa External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (40 g): $150.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Renova External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.02% (40 g): $244.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Renova Pump External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.02% (44 g): $258.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Retin-A External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (20 g): $143.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (20 g): $160.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (20 g): $187.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tretin-X External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.0375% (35 g): $232.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Tretinoin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (20 g): $42.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (20 g): $50.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (20 g): $58.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Atralin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (45 g): $331.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Avita External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (20 g): $101.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Retin-A External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (15 g): $113.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (15 g): $114.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Retin-A Micro External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.04% (20 g): $337.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (20 g): $337.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Retin-A Micro Pump External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.04% (50 g): $708.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (50 g): $708.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Tretinoin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.01% (15 g): $40.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% (15 g): $40.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Tretinoin Microsphere External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.04% (20 g): $300.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (20 g): $300.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Tretin-X External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025% cream (1): $218.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% cream (1): $248.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% cream (1): $264.18",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F230481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acfen-A (MX);",
"     </li>",
"     <li>",
"      Retacnyl (MX);",
"     </li>",
"     <li>",
"      Retin-A (MX);",
"     </li>",
"     <li>",
"      Stieva-A (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Keratinocytes in the sebaceous follicle become less adherent which allows for easy removal; inhibits microcomedone formation and eliminates lesions already present",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic for the small amount absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winston MH, Shalita AR, &ldquo;Acne Vulgaris, Pathogenesis and Treatment,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):889-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1862/abstract-text/1831256/pubmed\" id=\"1831256\" target=\"_blank\">",
"        1831256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10014 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1862=[""].join("\n");
var outline_f1_52_1862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230490\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230491\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230507\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230493\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230501\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230494\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230472\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230458\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230474\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230473\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230504\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230514\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230505\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230477\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230462\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230502\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230467\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230486\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230469\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230480\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230496\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230479\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230481\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230461\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230476\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10014\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10014|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/42/30372?source=related_link\">",
"      Topical tretinoin (topical all trans retinoic acid): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/10/43171?source=related_link\">",
"      Topical tretinoin (topical all trans retinoic acid): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_52_1863="Tenofovir and emtricitabine: Drug information";
var content_f1_52_1863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tenofovir and emtricitabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/46/32485?source=see_link\">",
"    see \"Tenofovir and emtricitabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/34/4647?source=see_link\">",
"    see \"Tenofovir and emtricitabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Truvada&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Truvada&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside);",
"     </li>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleotide)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Avoid concurrent use with adefovir or lamivudine-containing products or other emtricitabine- and/or tenofovir-containing products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV-1 infection:",
"     </b>",
"     Oral: One tablet (emtricitabine 200 mg and tenofovir 300 mg) once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as a component of preferred regimens (in combination with atazanavir/ritonavir or darunavir/ritonavir or efavirenz or raltegravir) in antiretroviral-naive patients (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Preexposure prophylaxis (PrEP) for prevention of HIV infection in uninfected high-risk individuals:",
"     </b>",
"     Oral: One tablet (emtricitabine 200 mg and tenofovir 300 mg) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatitis B treatment in patients with antiviral-resistant HBV or coinfection with HIV (unlabeled use):",
"     </b>",
"     Oral: One tablet (emtricitabine 200 mg and tenofovir 300 mg) once daily (Lok, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13168459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/34/4647?source=see_link\">",
"      see \"Tenofovir and emtricitabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Avoid concurrent use with adefovir or lamivudine-containing products or other emtricitabine- and/or tenofovir-containing products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV-1 infection:",
"     </b>",
"     Children &ge;12 years (&ge;35 kg) and Adolescents (&ge;35 kg): Oral: One tablet (emtricitabine 200 mg and tenofovir 300 mg) once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as a component of preferred regimens (in combination with atazanavir/ritonavir or darunavir/ritonavir or efavirenz or raltegravir) in antiretroviral-naive patients (DHHS, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F164685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     HIV-1 infection: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Increase interval to every 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or hemodialysis: Not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     PrEP: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9891673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No dosing adjustment necessary for tenofovir in moderate-to-severe hepatic compromise; no specific data available on emtricitabine in hepatic impairment, but given limited hepatic metabolism, dose adjustments are unlikely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Truvada&reg;: Emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14633101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312307.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312307.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F164671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents in adults and pediatric patients &ge;12 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-exposure prophylaxis (PrEP) for prevention of HIV-1 infection in adults who are at high risk for acquiring HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     High risk individuals include those with partners known to be HIV-1 infected or who engage in sexual activity within a high prevalence area or social network, and one or more of the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Inconsistent or no condom use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Diagnosis of sexually-transmitted infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Exchange of sex for commodities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Use of illicit drugs or alcohol dependence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Incarceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Partner of unknown HIV-1 status with any of the above risk factors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     When prescribing PrEP healthcare providers",
"     <b>",
"      MUST",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Include PrEP as part of a comprehensive prevention strategy because PrEP alone is not always effective in preventing HIV-1 infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Counsel all uninfected patients to strictly adhere to the dosing schedule, because adherence was strongly correlated with effectiveness in clinical trials",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Confirm a negative HIV-1 test prior to starting PrEP; if a candidate has acute viral infection symptoms and unprotected exposure events &lt;1 month prior, delay PrEP for at least 1 month and retest HIV-1 status or use an Food and Drug Administration (FDA) test approved for HIV-1 diagnosis, including acute or primary HIV-1 infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Retest for HIV-1 infection at least every 3 months while the patient receives PrEP",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F10419006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hepatitis B in patients with antiviral-resistant HBV or coinfection with HIV",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The adverse reaction profile of combination therapy has not been established. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Do not use for preexposure  prophylaxis in patients with unknown or HIV-1 positive status. For HIV-1 treatment, use only in HIV-1-infected patients in combination with other antiretrovirals.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-top:2em;\">",
"     Canadian labeling: Previously demonstrated hypersensitivity to any component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Use has been associated with decreases in bone mineral density (~5% to 7%) and osteomalacia. Consider monitoring of bone density in patients at risk for osteopenia or with a history of pathologic fractures; consider calcium and vitamin D supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside and nucleotide analogues (eg, tenofovir), including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: May cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy. Calculate creatinine clearance prior to initiation of therapy and monitor renal function (including recalculation of creatinine clearance and serum phosphorus) during therapy in all patients; monitor renal function during therapy (including recalculation of creatinine clearance and serum phosphorus) in patients at risk for renal impairment, including those with previous renal dysfunction on adefovir. Dosage adjustment required in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Safety and efficacy during coinfection of HIV and HBV have not been established; acute, severe exacerbations of HBV have been reported following discontinuation of antiretroviral therapy.",
"     </b>",
"     All patients with HIV should be tested for HBV prior to initiation of treatment. Caution in patients with known or suspected hepatitis B or C infection (monitoring of liver function is recommended). In HBV coinfected patients, acute HBV infection exacerbations have occurred following discontinuation; monitor hepatic function closely for several months following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Comprehensive prevention program:  Preexposure prophylaxis (PrEP) should be accompanied by a comprehensive HIV-1 prevention program (eg, risk reduction counseling, access to condoms), with particular emphasis on medication adherence. In addition, regular monitoring (eg, HIV status of patient and partner(s), risk behavior, adherence, adverse effects, sexually transmitted infections that facilitate HIV-1 transmission) is highly recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. No dosage adjustment is required; limited studies indicate the pharmacokinetics of tenofovir are not altered in hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV treatment: Appropriate use: Not recommended as a component of a triple nucleoside regimen due to potential for early virological failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV treatment and renal impairment: Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); dosage adjustment required. Do not use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PrEP and renal impairment: Routinely monitor patients with mild renal impairment. Calculate creatinine clearance prior to initiation in all patients; monitor renal function during therapy (including recalculation of creatinine clearance and serum phosphorus). Do not use in Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Resistance risk with PrEP:",
"     <b>",
"      [U.S. Boxed Warning]: Confirm HIV-1 negative status immediately before and at least every 3 months during therapy.",
"     </b>",
"     Risk of drug resistant HIV-1 variants with PrEP use if patient had undetected acute HIV-1 infection. Some HIV-1 tests (eg, rapid tests) do not detect acute HIV-1 infection. Screen PrEP candidates for acute viral infections and potential exposure events &le;1 month of starting PrEP. If infections or events exist, wait 1 month to start PrEP and reconfirm HIV-1 negative status. Do not start PrEP if signs or symptoms of acute HIV-1 infection are present unless HIV-1 negative status is confirmed by a test approved by the Food and Drug Administration (FDA) as an aid to detect HIV-1 infection (including acute or primary infection).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adefovir: Do not use concurrently with adefovir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Do not use concurrently with emtricitabine, tenofovir, or any combination of these drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lamivudine: Do not use concurrently with lamivudine or lamivudine-combination products.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adefovir: May diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir. Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Tenofovir may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Tenofovir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F164679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food decreases peak plasma concentrations, but does not alter the extent of absorption or overall systemic exposure.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although approved for use in combination with safer sex practices for the prevention of HIV-1 infection in adults who are at high risk for acquiring HIV (preexposure prophylaxis [PrEP]), data on use in heterosexual HIV serodiscordant couples wishing to conceive are limited. In addition, preconception use of PrEP in the uninfected partner when the HIV-infected partner is receiving antiretroviral therapy has not been studied.  Women of reproductive age should have a pregnancy test prior to starting PrEP and at regular intervals during therapy. In addition to pregnancy testing, uninfected women considering PrEP therapy should also undergo screening for HIV and other sexually transmitted diseases. Serodiscordant couples wishing to conceive should seek expert consultation to determine the safest approach for their specific situation.  If HIV infection is documented during PrEP therapy, the antiretroviral agents should be discontinued in order to minimize drug resistance. If pregnancy is detected during therapy, the potential risks and benefits of continuing PrEP during pregnancy should be discussed (DHHS [perinatal], 2012; CDC, 2012). Refer to individual monographs for additional information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F164688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in combination with safer sex practices for preexposure prophylaxis (PrEP) in lactating women who are HIV-uninfected is limited (DHHS [perinatal], 2012).  Use is not recommended (CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F164676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F164677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Consider calcium and vitamin D supplementation in patients with history of bone fracture or osteopenia.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Truvada Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-300 mg (30): $1467.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F164667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, reticulocyte count, serum creatine kinase, CD4 count, HIV RNA plasma levels, renal and hepatic function tests, bone density (long-term), serum phosphorus; testing for HBV is recommended prior to the initiation of antiretroviral therapy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients with HIV and HBV coinfection should be monitored for several months following tenofovir discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV-1 preexposure prophylaxis (PrEP) (CDC, 2011; CDC, 2012): Pregnancy test for women receiving PrEP (every visit); documented negative HIV test (immediately prior to use, every 2-3 months, and following discontinuation of PrEP), assess risk behaviors and symptoms of sexually-transmitted infections (STIs) or acute HIV-1 infection and provide condoms (immediately prior to use, then every 2-3 months during therapy);  BUN and serum creatinine (prior to initiation, 3 months after initiation, then every 6 months); testing for HBV (prior to initiation) and STIs (prior to initiation, then at least every 6 months, even if asymptomatic)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Truvada (AR, AT, AU, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, MX, NL, NO, NZ, PT, RU, SE, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nucleoside and nucleotide reverse transcriptase inhibitor combination; emtricitabine is a cytosine analogue while tenofovir disoproxil fumarate (TDF) is an analog of adenosine 5'-monophosphate. Each drug interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual monographs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baeten JM, Donnell D, Ndase P, et al, &ldquo;Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(5):399-410.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1863/abstract-text/22784037/pubmed\" id=\"22784037\" target=\"_blank\">",
"        22784037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),&ldquo;Interim Guidance:  Preexposure Prophylaxis for the Prevention of HIV infection in Men Who Have Sex with Men&rdquo;.",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(3):65-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1863/abstract-text/21270743/pubmed\" id=\"21270743\" target=\"_blank\">",
"        21270743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61(31):586-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1863/abstract-text/22874836/pubmed\" id=\"22874836\" target=\"_blank\">",
"        22874836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grant RM, Lama JR, Anderson PL, et al, &ldquo;Pre-exposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex With Men&rdquo;,",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(27):2587-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1863/abstract-text/21091279/pubmed\" id=\"21091279\" target=\"_blank\">",
"        21091279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lok AS and McMahon BJ, &ldquo;Chronic Hepatitis B,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2007, 45(2):507- 39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1863/abstract-text/17256718/pubmed\" id=\"17256718\" target=\"_blank\">",
"        17256718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Microbicide Trials Network (MTN), &ldquo;MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women,&rdquo;",
"      <i>",
"       Microbicide Trials Network",
"      </i>",
"      , 2011.  Available at file://www.mtnstopshiv.org/node/3619.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thigpen MC, Kebaabetswe PM, Paxton LA, et al, &ldquo;Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(5):423-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1863/abstract-text/22784038/pubmed\" id=\"22784038\" target=\"_blank\">",
"        22784038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Damme L, Corneli A, Ahmed K, et al, &ldquo;Preexposure Prophylaxis for HIV Infection Among African Women,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(5):411-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/52/1863/abstract-text/22784040/pubmed\" id=\"22784040\" target=\"_blank\">",
"        22784040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8527 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1863=[""].join("\n");
var outline_f1_52_1863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708729\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164681\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934286\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164696\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164683\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13168459\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164684\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164685\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9891673\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164669\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164659\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14633101\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164671\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164670\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10419006\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164694\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164674\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164661\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299259\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164664\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164679\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164666\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164675\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164688\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164676\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164677\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422225\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164667\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301432\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164660\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164673\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8527|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/46/32485?source=related_link\">",
"      Tenofovir and emtricitabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/34/4647?source=related_link\">",
"      Tenofovir and emtricitabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_52_1864="Chart for medication management";
var content_f1_52_1864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Chart for medication management",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: DeWalt DA, Malone RM, Bryant ME, et al. A heart failure self-management program for patients of all literacy levels: a randomized, controlled trial. BMC Health Serv Res 2006; 6:30. Copyright &copy; 2006 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1864=[""].join("\n");
var outline_f1_52_1864=null;
var title_f1_52_1865="Musculoskeletal screen 2";
var content_f1_52_1865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    The pGALS musculoskeletal screen (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 715px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     pGALS: pediatric Gait Arms Legs Spine.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Foster, HE, Jandial, S. pGALS - A Screening Examination of the Musculoskeletal System in School-Aged Children. Reports on the Rheumatic Diseases (Series 5), Hands On 15. Arthritis Research Campaign; 2008 June. Copyright &copy;2008 Arthritis Research Campaign.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1865=[""].join("\n");
var outline_f1_52_1865=null;
var title_f1_52_1866="Clinical manifestations and diagnosis of lymphedema";
var content_f1_52_1866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of lymphedema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/52/1866/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/52/1866/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/52/1866/contributors\">",
"     Tammy E Mondry, DPT, MSRS, CLT-LANA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/52/1866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/52/1866/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/52/1866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/52/1866/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/52/1866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema is defined as the interstitial collection of protein-rich fluid due to disruption of lymphatic flow. There are both primary and secondary causes of lymphedema.",
"   </p>",
"   <p>",
"    The etiology, risk factors, clinical manifestations, classification, diagnosis, and differential diagnosis of lymphedema will be reviewed here. The prevention and treatment of lymphedema, the operative management of primary and secondary lymphedema, and an overview of the pathophysiology and etiology of generalized edema are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29177?source=see_link\">",
"     \"Operative management of primary and secondary lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link\">",
"     \"Pathophysiology and etiology of edema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY OF THE LYMPHATIC SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78308857\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymph draining from both lower extremities, the gastrointestinal tract, and the left upper body (upper extremity, chest wall, upper back, shoulder, and breast) enter the venous circulation through the thoracic duct, which opens into the venous angle between the left subclavian vein and left internal jugular vein (",
"    <a class=\"graphic graphic_figure graphicRef57280 \" href=\"UTD.htm?9/19/9525\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/1\">",
"     1",
"    </a>",
"    ]. The lymph draining from the right upper body drains into the right venous angle via the right lymphatic duct.",
"   </p>",
"   <p>",
"    In the extremities, there is a superficial lymphatic system that drains the skin and subcutaneous tissue and a deep system that drains subfascial structures such as muscle and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The two systems of the upper extremities merge in the axilla and the two systems of the lower extremities merge in the pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213979537\">",
"    <span class=\"h2\">",
"     Physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the high pressure of vascular flow in the systemic circulation, lymph flow takes place in a low pressure system. Uptake of interstitial fluid begins in lymphatic capillaries and precollectors that abut the interstitial space. This process is facilitated by local arterial pulsation, skeletal muscle contraction, and unidirectional valves that prevent backward flow. The initial lymphatics merge into vessels of increasing caliber equipped with a smooth muscle coat which, on contraction, promote peristaltic movement of the lymph fluid toward the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1652245637\">",
"    <span class=\"h2\">",
"     Physiologic basis of lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema occurs when the lymphatic load exceeds the transport capacity of the lymphatic system, which causes filtered fluid to accumulate in the interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/1\">",
"     1",
"    </a>",
"    ]. As opposed to generalized edematous states, the rate of capillary filtration is normal in patients with lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRIMARY LYMPHEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lymphedema is due to a congenital",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inherited condition associated with pathologic development of the lymphatic vessels.",
"   </p>",
"   <p>",
"    Primary lymphedema is classified by the age at onset. Congenital lymphedema is defined by swelling that has an onset at birth up to two years. Lymphedema praecox typically arises during puberty or pregnancy with onset prior to age 35 years, and lymphedema tarda presents with an onset after age 35. Conditions associated with primary lymphedema in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link&amp;anchor=H87257370#H87257370\">",
"     \"Pathophysiology and etiology of edema in children\", section on 'Primary lymphedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of primary lymphedema in those attending lymphedema clinics ranges from 8 percent among all newly diagnosed patients to 28 percent of those with non-cancer related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/4\">",
"     4",
"    </a>",
"    ]. These conditions involve the lower limbs preferentially, with the exception of lymphedema tarda [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/3\">",
"     3",
"    </a>",
"    ]. Primary upper limb lymphedema has been rarely reported. In one series of 60 patients seen in one lymphedema center, the mean age at diagnosis was 38 years (range, 3 to 82 years) and the female to male ratio was 1.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of cases were not associated with a genetic condition. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213980183\">",
"    <span class=\"h1\">",
"     SECONDARY LYMPHEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema that occurs as the result of other conditions or treatments is called secondary lymphedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H213980340\">",
"    <span class=\"h2\">",
"     Etiology and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the developed world, nearly all cases of secondary lymphedema are due to malignancy or its treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/6\">",
"     6",
"    </a>",
"    ]. Worldwide, the most common cause of secondary lymphedema worldwide is filariasis, due to infection by the nematode",
"    <em>",
"     Wuscheria bancrofti",
"    </em>",
"    . &nbsp;",
"   </p>",
"   <p>",
"    Other risk factors for lymphedema include older age, obesity, and inflammatory arthritis. In addition to raising the risk of developing lymphedema, these factors contribute to an increased likelihood of worsening symptoms in patients already affected with lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H802872645\">",
"     'Inflammatory arthritis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H802872652\">",
"     'Obesity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H884706130\">",
"    <span class=\"h3\">",
"     Cancer and cancer treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer-associated lymphedema can occur in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstruction of lymphatic channels or nodes &mdash; Tumor compression of lymphatic channels or nodes can result in the development of lymphedema.",
"     </li>",
"     <li>",
"      Infiltration of lymphatic vessels &mdash; Tumor cells can infiltrate the lymphatic channels (also called lymphangitic carcinomatosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common cancer associated with lymphedema is breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/10\">",
"     10",
"    </a>",
"    ]. However, other malignancies are associated with an increased risk of lymphedema. This was illustrated in a 2010 meta-analysis that found the overall incidence of lymphedema in non-breast malignancies was 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/11\">",
"     11",
"    </a>",
"    ]. The incidence of lymphedema associated with specific malignancies was reported as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sarcoma &mdash; 30 percent",
"     </li>",
"     <li>",
"      Lower extremity melanoma &mdash; 28 percent",
"     </li>",
"     <li>",
"      Gynecologic cancer &mdash; 20 percent",
"     </li>",
"     <li>",
"      Genitourinary cancer &mdash; 10 percent",
"     </li>",
"     <li>",
"      Head and neck cancer &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to obstruction or infiltration of the primary malignancy, surgical removal of lymph nodes (lymphadenectomy) and radiation therapy (RT) can increase the risk of lymphedema in patients with cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2083648074\">",
"    <span class=\"h4\">",
"     Lymphadenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenectomy is perhaps the strongest predictor of lymphedema, and it is associated with an increased risk of lymphedema regardless of the cancer type. It is the primary cause of lymphedema in patients with breast cancer, prostate cancer, endometrial cancer, cervical cancer, endometrial cancer, and melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/1,4,12,13\">",
"     1,4,12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H6#H6\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Staging and primary surgical treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=see_link\">",
"     \"Management of locally advanced cervical cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H24077780#H24077780\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Pelvic lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients treated for breast cancer, the risk of lymphedema is not affected by whether a mastectomy or breast conserving surgery is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. However, the risk is greatest following an axillary node dissection rather than a sentinel lymph node biopsy (SLNB). The overall rate of arm edema associated solely with axillary node dissection is approximately 20 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fortunately, contemporary surgical treatment of breast cancer does not automatically mandate axillary node dissection in women with a clinically node-negative axilla. Instead, most women undergo SLNB, which is associated with a 64 percent lower risk of lymphedema compared to axillary node dissection (odds ratio [OR] 0.36, 95% CI 0.15-0.86) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beyond lymphadenectomy, the likelihood of developing lymphedema is related to other preoperative and postoperative factors including [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Extent of primary surgery",
"     </li>",
"     <li>",
"      Tumor location",
"     </li>",
"     <li>",
"      Delayed wound healing",
"     </li>",
"     <li>",
"      Postoperative infection",
"     </li>",
"     <li>",
"      Postoperative hematoma or seroma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2083648067\">",
"    <span class=\"h4\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased risk for lymphedema in patients treated with radiation therapy (RT) is best illustrated in breast cancer patients. In a 2001 systematic review, there was a statistically significantly higher rate of lymphedema among women who underwent surgery plus axillary RT compared to surgery alone (41 versus 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with breast cancer, RT is an additive risk factor for those who have undergone axillary node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/14,18,19\">",
"     14,18,19",
"    </a>",
"    ]. In one report, the incidence of subjective lymphedema was 7 and 38 percent with axillary node dissection alone and axillary node dissection plus RT, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H730200#H730200\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits of regional nodal irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women undergoing breast conserving therapy are at risk for lymphedema following adjuvant RT. A retrospective study involved 1497 women treated for breast cancer between 1980 and 2006 (75 percent with node-negative breast cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/20\">",
"     20",
"    </a>",
"    ]. For the entire cohort, the reported incidence of lymphedema was 7 percent. For women treated with supraclavicular, axillary, and internal mammary RT, the incidence was 10, 15, and 8 percent. Factors significantly associated with an increased risk of lymphedema included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pathologically involved nodes (11 versus 6 percent if nodes were negative)",
"     </li>",
"     <li>",
"      Removal of more than 14 nodes at surgery (9.5 versus 6 percent)",
"     </li>",
"     <li>",
"      Presence of extracapsular extension (13.4 versus 6.9 percent)",
"     </li>",
"     <li>",
"      Grade 2 or 3 breast tumor (11 versus 3 percent)",
"     </li>",
"     <li>",
"      Administration of adjuvant chemotherapy (10.5 versus 7 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802872638\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious causes of lymphedema are more common in tropical and subtropical regions. Parasitic infections can result in lymphatic obstruction, and filariasis is the most common cause of this worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\", section on 'Lymphedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beyond parasitic infections, recurrent skin infections (eg, cellulitis) may also cause a complication of lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H13#H13\">",
"     \"Cellulitis and erysipelas\", section on 'Recurrent cellulitis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H802871848\">",
"     'Skin infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802872645\">",
"    <span class=\"h3\">",
"     Inflammatory arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper or lower extremity lymphedema, which can be unilateral or bilateral, is a rare extra-articular manifestation of inflammatory joint disease, and is most often reported in patients with rheumatoid arthritis or psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/22-28\">",
"     22-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of lymphedema associated with rheumatoid arthritis is not known, but inflammatory synovitis leading to fibrosis of lymph vessels has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/29\">",
"     29",
"    </a>",
"    ]. In some patients, the lymphedema improves with effective treatment of the arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/27-29\">",
"     27-29",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H36#H36\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Lymphatic obstruction'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    A similar clinical appearance is seen as a result of extensive tenosynovitis in patients with psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802872652\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is an independent risk factor for lymphedema, particularly in cancer survivors. As an example, in a study of 137 women treated for breast cancer, women with a BMI &gt;30 had an increased risk of lymphedema compared to women with BMI &lt;25 (OR, 2.93, 95% CI 1.03-8.31) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Morbid obesity is associated with a recently described clinical entity called massive localized lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. This typically presents as a painless and long-standing lesion of the thigh. Pathologically, it is characterized by dermal thickening and an ill-defined, unencapsulated, large mass [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical signs and symptoms of lymphedema include [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset &mdash; The onset of lymphedema is usually insidious. Affected patients may initially experience aching pain at the affected area and a sense of heaviness or fullness of the limb. Over time, the skin becomes dry and firm with less pitting and is fibrous to palpation.",
"     </li>",
"     <li>",
"      Laterality &mdash; Two-thirds of cases of lymphedema are unilateral, although the laterality depends on the precipitating event [",
"      <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/35\">",
"       35",
"      </a>",
"      ]. For example, an axillary node dissection will increase the risk of lymphedema in the ipsilateral arm while a pelvic node dissection increases the risk of bilateral lower extremity edema.",
"     </li>",
"     <li>",
"      Swelling &mdash; At onset, swelling in the affected limb is typically characterized as &ldquo;soft&rdquo; and &ldquo;pitting&rdquo;. Pitting is variable in patients with lymphedema and reflects movement of the excess interstitial water in response to pressure. It is generally absent with progressive lymphedema, reflecting the evolution of fibrosis and adipose tissue deposition.",
"      <br/>",
"      <br/>",
"      For patients who had previously undergone a lymph node dissection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation, lymphedema is typically characterized by slowly progressive ipsilateral swelling of an arm following axillary node dissection or a leg following inguinal node dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/2\">",
"       2",
"      </a>",
"      ]. The swelling may first be apparent only in the proximal portion of the limb, or it can affect only a portion of the distal limb including the digits.",
"      <br/>",
"      <br/>",
"      Among patients with breast cancer, there may also be swelling over the ipsilateral breast",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      upper chest wall. Other manifestations include a feeling of heaviness, tightness, aching or discomfort in the limb, and restricted range of motion.",
"     </li>",
"     <li>",
"      Skin changes &mdash; With worsening lymphedema, dermal thickening becomes clinically apparent, which is manifested by cutaneous fibrosis. The overlying skin of the affected limb also becomes hyperkeratotic, which can lead to verrucous and vesicular skin lesions.",
"     </li>",
"     <li>",
"      Discomfort &mdash; A feeling of heaviness, tightness, aching or discomfort in the affected limb commonly accompanies swelling.",
"     </li>",
"     <li>",
"      Restricted range of motion &mdash; With later stages of lymphedema, patients may develop restricted range of motion in the affected limb as a result of the increased weight, which may limit their ability to perform activities of daily living (ADLs).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema is staged using the criteria of the International Society of Lymphology [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/36\">",
"     36",
"    </a>",
"    ]. This involves two criteria to diagnose and classify lymphedema: the \"softness\" or \"firmness\" of the limb (reflecting fibrotic soft tissue changes) and the outcome after elevation: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 0 &mdash; Stage 0 lymphedema is a subclinical or latent condition where swelling is not evident despite impaired lymphatic transport. Most patients are asymptomatic, but some report a feeling of heaviness in the limb. Stage 0 may exist for months or years before the onset of overt lymphedema occurs (stage I to III).",
"     </li>",
"     <li>",
"      Stage I - Stage I lymphedema is characterized by the accumulation of fluid that subsides with 24-hour limb elevation (",
"      <a class=\"graphic graphic_picture graphicRef56739 \" href=\"UTD.htm?12/11/12471\">",
"       picture 1",
"      </a>",
"      ). The appearance is that of soft edema that may pit, with no evidence of dermal fibrosis. This is sometimes called reversible edema.",
"     </li>",
"     <li>",
"      Stage II - Stage II lymphedema does not resolve with 24-hour limb elevation alone (",
"      <a class=\"graphic graphic_picture graphicRef76706 \" href=\"UTD.htm?29/15/29942\">",
"       picture 2",
"      </a>",
"      ). This reflects the evolution of dermal fibrosis. As the fibrosis progresses, the limb may no longer pit on examination. This is sometimes called spontaneously irreversible lymphedema.",
"     </li>",
"     <li>",
"      Stage III - Stage III lymphedema is characterized by lymphostatic elephantiasis. On exam, pitting is absent, and the skin reveals trophic skin changes such as fat deposits, acanthosis, and warty overgrowths (",
"      <a class=\"graphic graphic_picture graphicRef63928 \" href=\"UTD.htm?3/2/3112\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within each stage, severity based upon volume differences is assessed as minimal (&lt;20 percent increase), moderate (20 to 40 percent increase), or severe (&gt;40 percent increase). (See",
"    <a class=\"local\" href=\"#H857615700\">",
"     'Clinical measurements'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384249139\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classification systems are used to describe the severity of lymphedema, including the American Physical Therapy Association (APTA) and National Cancer Institute&rsquo;s Common Terminology Criteria for Adverse Events (CTCAE). Of these, we prefer the APTA classification system. Both schemas are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384249166\">",
"    <span class=\"h3\">",
"     American Physical Therapy Association (APTA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The APTA uses girth as an anthropometric measurement to classify lymphedema. The maximum girth difference between the affected and unaffected limb is used to determine the class of lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/37\">",
"     37",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H802881735\">",
"     'Circumferential measurements'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild lymphedema &mdash; maximum girth difference &lt;3 cm",
"     </li>",
"     <li>",
"      Moderate lymphedema &mdash; 3 to 5 cm difference",
"     </li>",
"     <li>",
"      Severe lymphedema &mdash; difference &gt;5 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802874472\">",
"    <span class=\"h3\">",
"     National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Cancer Institute CTCAE categorizes lymphedema based upon exam findings and the presence of functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 1 &mdash; Trace thickening or faint discoloration",
"     </li>",
"     <li>",
"      Grade 2 &mdash; Marked discoloration; leathery skin texture; papillary formation; limiting instrumental activities of daily living (ADL)",
"     </li>",
"     <li>",
"      Grade 3 &mdash; Severe symptoms limiting self care ADL",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802880404\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical findings of asymmetric measurements can usually establish a diagnosis of lymphedema. Clinical measurements of girth or estimates of lymphedema volume are necessary to establish baseline and to track changes during treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention and treatment of lymphedema\", section on 'Treatment'",
"    </a>",
"    .). We reserve imaging for cases in which the history and exam do not yield a definitive diagnosis or in cases where lymphatic obstruction (ie, due to tumor) is suspected. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802880717\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful medical history is critical in the evaluation of the patient with suspected lymphedema. Components of the history that should be addressed include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age of onset",
"     </li>",
"     <li>",
"      Area(s) of involvement",
"     </li>",
"     <li>",
"      Associated symptoms (eg, pain)",
"     </li>",
"     <li>",
"      Medications &mdash; While none is directly associated with an increased risk of lymphedema, some are associated with edematous states (eg, nonsteroidal antiinflammatory agents) or are contraindicated in the treatment of lymphedema (eg, diuretics). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathophysiology and etiology of edema in adults\", section on 'Drug-induced edema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progression of symptoms",
"     </li>",
"     <li>",
"      Past medical history, including of medical conditions associated with lymphedema, any prior travel, infections, surgery or prior RT",
"     </li>",
"     <li>",
"      Family history",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802880725\">",
"    <span class=\"h2\">",
"     Physical exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical exam should evaluate the vascular system, skin, and soft tissue, and palpation of the lymph nodes.",
"   </p>",
"   <p>",
"    If primary lymphedema is suspected, evaluation should include documentation of any physical signs or congenital anomalies associated with an inherited condition. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short stature (Turner Syndrome)",
"     </li>",
"     <li>",
"      Port wine stains or hemangiomas (Klippel-Trenaunay-Weber Syndrome)",
"     </li>",
"     <li>",
"      Shield chest (Turner Syndrome, Noonan Syndrome)",
"     </li>",
"     <li>",
"      A positive Stemmer sign is indicative of lymphedema [",
"      <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/39\">",
"       39",
"      </a>",
"      ]. It is characterized by the examiner&rsquo;s inability to lift the skin of the affected limb compared to the contralateral limb. It is also described as difficulty lifting the skin of the dorsum of the fingers or toes of the affected limb (",
"      <a class=\"graphic graphic_picture graphicRef63928 \" href=\"UTD.htm?3/2/3112\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/40\">",
"       40",
"      </a>",
"      ]. A positive Stemmer sign can be found in any stage of lymphedema. While it is possible to have a false negative Stemmer sign, a false positive sign is rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H857615700\">",
"    <span class=\"h2\">",
"     Clinical measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of limb volume are commonly used for the diagnosis of limb edema and for monitoring during and after therapy, particularly arm edema in patients with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .). Limb volume can be measured by the water displacement method or estimated by taking several circumferential measurements at standard distances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In our practice, we use optoelectronic volumetry to document limb volume.",
"   </p>",
"   <p>",
"    Methods to obtain clinical measurements are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H384249248\">",
"    <span class=\"h3\">",
"     Optoelectronic volumetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume can be assessed utilizing an infrared, optoelectronic measurements. This technique utilizes infrared beams to scan the limb and calculate a volume. The optoelectronic volumetry method has been found to have better reliability than water displacement volumetry in the measurement of upper extremity lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802881735\">",
"    <span class=\"h3\">",
"     Circumferential measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumferential measurements on the affected and contralateral arm are a simple and inexpensive method to estimate edema. Measurements can be taken at any point in the arm or leg, or circumferentially around the head, neck, or trunk, as long as the clinician is utilizing anatomic landmarks to reproduce the measurements. The measurements can be used to classify lymphedema severity using the American Physical Therapists Association classification system. (See",
"    <a class=\"local\" href=\"#H384249166\">",
"     'American Physical Therapy Association (APTA)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Measurements in the arm are made at four points in both the affected and contralateral arm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Metacarpal-phalangeal joints",
"     </li>",
"     <li>",
"      Wrists",
"     </li>",
"     <li>",
"      Ten centimeters distal to the lateral epicondyles",
"     </li>",
"     <li>",
"      Fifteen centimeters proximal to the lateral epicondyles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with arm lymphedema, a difference of more than 2 cm between the affected and contralateral arm is considered clinically significant. Changes in circumference may be more difficult to detect in obese women. In addition, they are subject to variation due to differences in muscle mass as a result of hand dominance and shifting of fluid proximally or distally due to arm positioning",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    compression. &nbsp;",
"   </p>",
"   <p>",
"    It is possible to estimate volume by the measurement of limb circumference, and data suggest that circumferential measurements correlated well with volume measurements by water displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. An",
"    <a class=\"external\" href=\"file://armvolume.com/\">",
"     on-line calculator",
"    </a>",
"    to assess arm lymphedema by circumference is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802881756\">",
"    <span class=\"h3\">",
"     Water displacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water displacement detects changes in volume of less than 1 percent. For patients with limb lymphedema, volume difference of 200 mL or more between the affected and opposite limbs is typically considered as a cutoff point to define lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/19,41,43\">",
"     19,41,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This method is the usual method to measure arm lymphedema on clinical trials. Traditional volumeters are cumbersome because they are large, expensive, and prone to leaks. However, an alternative, home-made, and smaller device has been developed that is as accurate and is suitable for home or office use (",
"    <a class=\"graphic graphic_figure graphicRef54531 \" href=\"UTD.htm?13/59/14262\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53493 \" href=\"UTD.htm?25/2/25646\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802881837\">",
"    <span class=\"h3\">",
"     Bioimpedance spectroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bioimpedance spectroscopy (BIS) is a reliable and accurate tool to determine volume. Using electrical current, resistance measurements are used to compare the composition of fluid compartments [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. It has been predominantly used to evaluate arm edema in patients with breast cancer, but impedance ratio thresholds for lymphedema of the legs have also been established [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802881770\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging modalities including computerized tomography (CT), magnetic resonance imaging (MRI), and lymphoscintigraphy have been used in the diagnostic work-up of lymphedema. Of these, lymphoscintigraphy is rarely used, due to the lack of standardization in the interpretation of the results.",
"   </p>",
"   <p>",
"    Computed tomography (CT) scan can demonstrate accumulation of fluid within soft tissue with good sensitivity. In one study of 55 patients who underwent both CT and lymphoscintigraphy, CT had a sensitivity and specificity of 93 and 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/54\">",
"     54",
"    </a>",
"    ]. &nbsp;Major CT findings for patients with lymphedema were: skin thickening (95 percent), subcutaneous edema accumulation (95 percent), and a honeycombed appearance (41 percent).",
"   </p>",
"   <p>",
"    MRI has also been used in the evaluation of lymphedema. Features of lymphedema on MRI include circumferential edema, increased volume of the subcutaneous tissue, honeycombing between the muscle and skin, and marked thickening of the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802880411\">",
"    <span class=\"h3\">",
"     Lymphoscintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoscintigraphy is a technique used to image the flow of fluid from the skin to the lymph nodes, particularly in the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/2\">",
"     2",
"    </a>",
"    ]. Subcutaneous or intradermal radioactive tracers are injected in the web space of the extremities and imaging is performed 30 to 60 minutes after injection. The patient then performs a stress activity (such as walking, massage, or squeezing a ball for about 20 minutes), which is followed by repeat imaging. Criteria for impaired lymphatic function include delayed, asymmetric, or absent visualization of the regional lymph nodes and dermal backflow.",
"   </p>",
"   <p>",
"    Quantitation of regional lymph node accumulation of the tracer appears to be more sensitive than qualitative lymphoscintigraphy (100 versus 70 percent in a series of 219 patients with secondary or primary lymphedema) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/55\">",
"     55",
"    </a>",
"    ]. All cases missed with qualitative lymphoscintigraphy were mild grade I disease. However, the protocol for lymphoscintigraphy is not standardized and differs among major centers. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40511035\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients diagnosed with primary lymphedema or suspected of lymphedema tarda, referral to a medical geneticist or genetic counselling service is suggested for evaluation of the family history and recommendations for further work-up [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802874506\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of lymphedema includes conditions associated with peripheral edema. The presence of lymphedema is usually suggested by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized rather than generalized edema. The edema is typically characterized by slowly progressive ipsilateral (unilateral) swelling of an arm following axillary node dissection or a leg following inguinal node dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/2\">",
"       2",
"      </a>",
"      ]. Other causes of localized limb swelling, such as deep vein thrombosis, malignancy (which may obstruct proximal lymphatic vessels), and infection should be evaluated with appropriate studies. Patients in endemic areas should be tested for filarial infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of trauma or cancer treatment. This includes surgical therapy, including axillary or inguinal lymph node dissection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT.",
"     </li>",
"     <li>",
"      The absence of a cause of generalized edema (eg, heart failure, nephrotic syndrome).",
"     </li>",
"     <li>",
"      The presence of cutaneous and subcutaneous thickening, which is usually seen in late or established lymphedema [",
"      <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The edema should be classified as pitting or nonpitting. Pitting reflects movement of the excess interstitial water in response to pressure. Testing for pitting involves applying firm pressure to the edematous tissue for at least five seconds. If an indentation remains after the pressure is released, pitting edema is present.",
"   </p>",
"   <p>",
"    Nonpitting edema is suggestive of lymphedema or venous insufficiency. However, the presence of pitting does NOT exclude lymphedema since, as noted above, pitting is present in lymphedema patients with stage I disease and in some with stage II disease. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Staging'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of edema in adults\", section on 'Venous insufficiency or thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and diagnosis of edema in adults\", section on 'Nonpitting edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasional patients have both lymphedema and generalized edema, such as cancer patients who have undergone a lymphadenectomy and have an established diagnosis of congestive heart failure. In this setting, concurrent lymphedema is suggested by asymmetric swelling in the limbs, with more swelling in the limb where the lymphadenectomy was performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other conditions that mimic lymphedema are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802874560\">",
"    <span class=\"h2\">",
"     Acute deep venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic symptoms of a deep venous thrombosis (DVT) include acute swelling, pain, and erythema involving one limb. The onset of edema and the associated symptoms (eg, acute erythema, calf pain) readily distinguishes DVT from lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802874522\">",
"    <span class=\"h2\">",
"     Post-thrombotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-thrombotic syndrome (PTS) is the development of chronic venous symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs secondary to deep venous thrombosis. These include pain, venous dilation, edema, pigmentation, skin changes and venous ulcers. A prior history of DVT can distinguish this condition from lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=see_link\">",
"     \"Post-thrombotic (postphlebitic) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802874575\">",
"    <span class=\"h2\">",
"     Limb hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several syndromes are characterized by hypertrophy of the soft tissue and bones (ie, Klippel-Trenaunay syndrome), overgrowth of body parts in a disproportionate fashion (ie, Proteus syndrome), and may affect one or more limb [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. These syndromes are associated with other clinical manifestations, such as capillary malformations, which may help to distinguish it from lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2217?source=see_link\">",
"     \"Capillary malformations (port wine stains): Clinical features, diagnosis, and associated syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802874616\">",
"    <span class=\"h2\">",
"     Lipedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipedema is a rare adipose disorder characterized as the abnormal deposition of fat with associated edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/59\">",
"     59",
"    </a>",
"    ]. It almost exclusively occurs in women and is associated with minimal pitting edema. Patients may complain of pain and tenderness and sustain easy bruising. Elevating the limbs has no effect on the affected limbs. A 2010 pedigree analysis suggests it is inherited as an X-linked dominant or autosomal dominant condition with sex limitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802871841\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema can result in multiple infectious complications and a rare form of sarcoma. It can also result in significant psychological comorbidity with a negative impact on quality of life. These complications are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802871848\">",
"    <span class=\"h2\">",
"     Skin infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedematous skin is at risk for recurrent infections, including cellulitis, erysipelas, and lymphangitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/3,61-65\">",
"     3,61-65",
"    </a>",
"    ]. Cellulitis is a well described complication of lymphedema, particularly in patients who have undergone axillary or inguinal lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Typical manifestations include erythema, pain, and tenderness. However, systemic signs, such as fever, may not be present. Although this is a complication, it is also a risk factor for both the onset and progression of lymphedema. (See",
"    <a class=\"local\" href=\"#H802872638\">",
"     'Infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802871855\">",
"    <span class=\"h2\">",
"     Lymphangiosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare secondary malignant tumor, called lymphangiosarcoma, can occur in patients with chronic lymphedema. It is usually seen in patients with massive and protracted edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/68\">",
"     68",
"    </a>",
"    ]. It is classically described as occurring in the postmastectomy patient (Stewart-Treves syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. It has also been described with primary lymphedema and chronic filarial lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link&amp;anchor=H751986#H751986\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Lymphedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tumor originates in vascular endothelial cells of the affected arm with lymphedema, not the lymphatic vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/70\">",
"     70",
"    </a>",
"    ]. It may initially appear as blue-red or purple skin lesions with a macular or papular shape. Multiple lesions are common and subcutaneous nodules may appear. Such skin lesions should be carefully evaluated in patients with chronic lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H802871877\">",
"    <span class=\"h2\">",
"     Psychological morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema results in psychological morbidity and a reduced quality of life including aspects of emotional, functional, physical and social well being [",
"    <a class=\"abstract\" href=\"UTD.htm?1/52/1866/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Psychological problems seen in women with chronic lymphedema after treatment for breast cancer include anxiety, depression, sexual dysfunction, social avoidance, and exacerbation of existing psychiatric illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/1/24594?source=see_link\">",
"       \"Patient information: Lymphedema after breast cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"       \"Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphedema is a progressive disorder of the lymphatic system that results in the interstitial collection of protein-rich fluid (lymph) that can lead to adipose tissue hypertrophy and fibrosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary lymphedema is associated with genetic or inherited conditions, all of which are associated with lymphatic disruption. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Primary lymphedema'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=see_link&amp;anchor=H87257370#H87257370\">",
"       \"Pathophysiology and etiology of edema in children\", section on 'Primary lymphedema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary lymphedema is due to underlying disease or as a consequence of prior treatment. In the United States, nearly all cases of lymphedema are secondary to malignancy or cancer therapy. The most common cause of lymphedema worldwide is filariasis, secondary to infection by the nematode",
"      <em>",
"       Wuscheria bancrofti",
"      </em>",
"      . (See",
"      <a class=\"local\" href=\"#H213980340\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of lymphedema include swelling, skin changes, discomfort, restricted range of motion, and nonpitting edema. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with limb edema, we use the staging system of the International Society of Lymphology to characterize lymphedema, which involves two criteria to diagnose and classify lymphedema: the \"softness\" or \"firmness\" of the limb (reflecting fibrotic soft tissue changes); and the reaction of the swelling to elevation. We also use the American Physical Therapy Association classification system to classify lymphedema as mild, moderate, or severe. This is based on the maximum girth difference between the affected and unaffected limb. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Staging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H384249166\">",
"       'American Physical Therapy Association (APTA)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of lymphedema can be made by history, physical exam, and clinical measurements of the affected versus unaffected limb. While imaging of the lymphatic system is usually not necessary to confirm the diagnosis of lymphedema, computed tomography can be helpful to distinguish lymphedema from non-lymphatic causes of edema. (See",
"      <a class=\"local\" href=\"#H802880404\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of lymphedema include acute deep venous thrombosis, post-thrombotic syndrome, limb hypertrophy, lipedema, peripheral edema due to other systemic illness, and drug-induced edema. (See",
"      <a class=\"local\" href=\"#H802874506\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of lymphedema include skin infections (cellulitis, erysipelas, and lymphangitis), lymphangiosarcoma, and reduced quality of life including aspects of emotional, functional, physical and social well being. (See",
"      <a class=\"local\" href=\"#H802871841\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/1\">",
"      Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin 2009; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/2\">",
"      Szuba A, Shin WS, Strauss HW, Rockson S. The third circulation: radionuclide lymphoscintigraphy in the evaluation of lymphedema. J Nucl Med 2003; 44:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/3\">",
"      Kerchner K, Fleischer A, Yosipovitch G. Lower extremity lymphedema update: pathophysiology, diagnosis, and treatment guidelines. J Am Acad Dermatol 2008; 59:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/4\">",
"      Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Ann N Y Acad Sci 2008; 1131:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/5\">",
"      Vignes S, Arrault M, Yannoutsos A, Blanchard M. Primary upper-limb lymphoedema. Br J Dermatol 2013; 168:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/6\">",
"      Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema: a comprehensive review. Ann Plast Surg 2007; 59:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/7\">",
"      Hayes SC, Janda M, Cornish B, et al. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol 2008; 26:3536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/8\">",
"      Deutsch M, Land S, Begovic M, Sharif S. The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys 2008; 70:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/9\">",
"      Bar Ad V, Cheville A, Solin LJ, et al. Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2010; 76:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/10\">",
"      R&ouml;nk&auml; RH, Pamilo MS, von Smitten KA, Leidenius MH. Breast lymphedema after breast conserving treatment. Acta Oncol 2004; 43:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/11\">",
"      Cormier JN, Askew RL, Mungovan KS, et al. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer 2010; 116:5138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/12\">",
"      Williams SK, Rabbani F. Complications of lymphadenectomy in urologic surgery. Urol Clin North Am 2011; 38:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/13\">",
"      Abu-Rustum NR, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/14\">",
"      Erickson VS, Pearson ML, Ganz PA, et al. Arm edema in breast cancer patients. J Natl Cancer Inst 2001; 93:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/15\">",
"      Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23:4312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/16\">",
"      Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 95:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/17\">",
"      McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 2008; 26:5213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/18\">",
"      Borup Christensen S, Lundgren E. Sequelae of axillary dissection vs. axillary sampling with or without irradiation for breast cancer. A randomized trial. Acta Chir Scand 1989; 155:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/19\">",
"      Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg 1986; 73:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/20\">",
"      Shah C, Wilkinson JB, Baschnagel A, et al. Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys 2012; 83:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/21\">",
"      Proske S, Uter W, Schwanitz HJ. [Secondary lymphedema of the hand as a complication of recurrent erysipelas in irritant contact dermatitis]. Hautarzt 2001; 52:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/22\">",
"      Joos E, Bourgeois P, Famaey JP. Lymphatic disorders in rheumatoid arthritis. Semin Arthritis Rheum 1993; 22:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/23\">",
"      Sant SM, Tormey VJ, Freyne P, Casey EB. Lymphatic obstruction in rheumatoid arthritis. Clin Rheumatol 1995; 14:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/24\">",
"      Kiely PD, Joseph AE, Mortimer PS, Bourke BE. Upper limb lymphedema associated with polyarthritis of rheumatoid type. J Rheumatol 1994; 21:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/25\">",
"      Mulherin DM, FitzGerald O, Bresnihan B. Lymphedema of the upper limb in patients with psoriatic arthritis. Semin Arthritis Rheum 1993; 22:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/26\">",
"      Salvarani C, Cantini F, Olivieri I, et al. Distal extremity swelling with pitting edema in psoriatic arthritis: evidence of 2 pathological mechanisms. J Rheumatol 1999; 26:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/27\">",
"      Lekpa FK, Economu-Dubosc A, Fevre C, et al. Efficacy of etanercept in lymphedema associated with psoriatic arthritis. J Rheumatol 2009; 36:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/28\">",
"      B&ouml;hm M, Riemann B, Luger TA, Bonsmann G. Bilateral upper limb lymphoedema associated with psoriatic arthritis: a case report and review of the literature. Br J Dermatol 2000; 143:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/29\">",
"      Ostrov BE. Beneficial effect of etanercept on rheumatoid lymphedema. Arthritis Rheum 2001; 44:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/30\">",
"      Helyer LK, Varnic M, Le LW, et al. Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients. Breast J 2010; 16:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/31\">",
"      Farshid G, Weiss SW. Massive localized lymphedema in the morbidly obese: a histologically distinct reactive lesion simulating liposarcoma. Am J Surg Pathol 1998; 22:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/32\">",
"      Asch S, James WD, Castelo-Soccio L. Massive localized lymphedema: an emerging dermatologic complication of obesity. J Am Acad Dermatol 2008; 59:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/33\">",
"      Modolin ML, Cintra W Jr, Paggiaro AO, et al. Massive localized lymphedema (MLL) in bariatric candidates. Obes Surg 2006; 16:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/34\">",
"      Manduch M, Oliveira AM, Nascimento AG, Folpe AL. Massive localised lymphoedema: a clinicopathological study of 22 cases and review of the literature. J Clin Pathol 2009; 62:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/35\">",
"      Tiwari A, Cheng KS, Button M, et al. Differential diagnosis, investigation, and current treatment of lower limb lymphedema. Arch Surg 2003; 138:152.",
"     </a>",
"    </li>",
"    <li>",
"     The diagnosis and treatment of peripheral lymphedema: 2003 consensus of the International Society of Lymphology Executive Committee www.u.arizona.edu/%7Ewitte/ISL.htm (Accessed on April 19, 2011).",
"    </li>",
"    <li>",
"     American Physical Therapy Association. Guide to physical therapist practice, 2nd, APTA, Alexandria, VA 2001.",
"    </li>",
"    <li>",
"     National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) available online at file://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     Weissleder H, Schuchhardt C. Lymphedema diagnosis and therapy, 2nd, Kagerer Kommunikation, Bonn, Germany 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/40\">",
"      Rockson SG. Diagnosis and management of lymphatic vascular disease. J Am Coll Cardiol 2008; 52:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/41\">",
"      Beaulac SM, McNair LA, Scott TE, et al. Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg 2002; 137:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/42\">",
"      Casley-Smith JR. Measuring and representing peripheral oedema and its alterations. Lymphology 1994; 27:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/43\">",
"      Boland R, Adams R. Development and evaluation of a precision forearm and hand volumeter and measuring cylinder. J Hand Ther 1996; 9:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/44\">",
"      Deltombe T, Jamart J, Recloux S, et al. Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. Lymphology 2007; 40:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/45\">",
"      Ancukiewicz M, Russell TA, Otoole J, et al. Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 2011; 79:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/46\">",
"      Harris SR, Hugi MR, Olivotto IA, et al. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ 2001; 164:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/47\">",
"      Lette J. A simple and innovative device to measure arm volume at home for patients with lymphedema after breast cancer. J Clin Oncol 2006; 24:5434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/48\">",
"      Moseley A, Piller N. Reliability of bioimpedance spectroscopy and tonometry after breast conserving cancer treatment. Lymphat Res Biol 2008; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/49\">",
"      Cornish B. Bioimpedance analysis: scientific background. Lymphat Res Biol 2006; 4:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/50\">",
"      Ward LC, Czerniec S, Kilbreath SL. Operational equivalence of bioimpedance indices and perometry for the assessment of unilateral arm lymphedema. Lymphat Res Biol 2009; 7:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/51\">",
"      Mayrovitz HN, Weingrad DN, Davey S. Local tissue water in at-risk and contralateral forearms of women with and without breast cancer treatment-related lymphedema. Lymphat Res Biol 2009; 7:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/52\">",
"      Ward LC, Dylke E, Czerniec S, et al. Confirmation of the reference impedance ratios used for assessment of breast cancer-related lymphedema by bioelectrical impedance spectroscopy. Lymphat Res Biol 2011; 9:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/53\">",
"      Ward LC, Dylke E, Czerniec S, et al. Reference ranges for assessment of unilateral lymphedema in legs by bioelectrical impedance spectroscopy. Lymphat Res Biol 2011; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/54\">",
"      Monnin-Delhom ED, Gallix BP, Achard C, et al. High resolution unenhanced computed tomography in patients with swollen legs. Lymphology 2002; 35:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/55\">",
"      Weissleder H, Weissleder R. Lymphedema: evaluation of qualitative and quantitative lymphoscintigraphy in 238 patients. Radiology 1988; 167:729.",
"     </a>",
"    </li>",
"    <li>",
"     Position Statement of the National Lymphedema Network: The Diagnosis and Treatment of Lymphedema. file://www.lymphnet.org/pdfDocs/nlntreatment.pdf (Accessed on May 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/57\">",
"      Cohen MM Jr. Proteus syndrome: an update. Am J Med Genet C Semin Med Genet 2005; 137C:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/58\">",
"      Schook CC, Mulliken JB, Fishman SJ, et al. Differential diagnosis of lower extremity enlargement in pediatric patients referred with a diagnosis of lymphedema. Plast Reconstr Surg 2011; 127:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/59\">",
"      Herbst KL. Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin 2012; 33:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/60\">",
"      Child AH, Gordon KD, Sharpe P, et al. Lipedema: an inherited condition. Am J Med Genet A 2010; 152A:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/61\">",
"      Vaillant L, Gironet N. [Infectious complications of lymphedema]. Rev Med Interne 2002; 23 Suppl 3:403s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/62\">",
"      Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/63\">",
"      Herpertz U. [Erysipelas and lymphedema]. Fortschr Med 1998; 116:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/64\">",
"      Masmoudi A, Maaloul I, Turki H, et al. Erysipelas after breast cancer treatment (26 cases). Dermatol Online J 2005; 11:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/65\">",
"      Kerketta AS, Babu BV, Rath K, et al. A randomized clinical trial to compare the efficacy of three treatment regimens along with footcare in the morbidity management of filarial lymphoedema. Trop Med Int Health 2005; 10:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/66\">",
"      Soo JK, Bicanic TA, Heenan S, Mortimer PS. Lymphatic abnormalities demonstrated by lymphoscintigraphy after lower limb cellulitis. Br J Dermatol 2008; 158:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/67\">",
"      Damstra RJ, van Steensel MA, Boomsma JH, et al. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg. Br J Dermatol 2008; 158:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/68\">",
"      Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma arising in chronic lymphedematous extremities. Cancer 1972; 30:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/69\">",
"      Stewart FW, Treves N. Classics in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin 1981; 31:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/70\">",
"      Tomita K, Yokogawa A, Oda Y, Terahata S. Lymphangiosarcoma in postmastectomy lymphedema (Stewart-Treves syndrome): ultrastructural and immunohistologic characteristics. J Surg Oncol 1988; 38:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/71\">",
"      Cozen W, Bernstein L, Wang F, et al. The risk of angiosarcoma following primary breast cancer. Br J Cancer 1999; 81:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/72\">",
"      Andersson HC, Parry DM, Mulvihill JJ. Lymphangiosarcoma in late-onset hereditary lymphedema: case report and nosological implications. Am J Med Genet 1995; 56:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/73\">",
"      D&uuml;rr HR, Pellengahr C, Nerlich A, et al. Stewart-Treves syndrome as a rare complication of a hereditary lymphedema. Vasa 2004; 33:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/74\">",
"      Muller R, Hajdu SI, Brennan MF. Lymphangiosarcoma associated with chronic filarial lymphedema. Cancer 1987; 59:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/75\">",
"      Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychological morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer 1993; 72:3248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/52/1866/abstract/76\">",
"      McWayne J, Heiney SP. Psychologic and social sequelae of secondary lymphedema: a review. Cancer 2005; 104:457.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 755 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1866=[""].join("\n");
var outline_f1_52_1866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PHYSIOLOGY OF THE LYMPHATIC SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78308857\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H213979537\">",
"      Physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1652245637\">",
"      Physiologic basis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRIMARY LYMPHEDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213980183\">",
"      SECONDARY LYMPHEDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H213980340\">",
"      Etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H884706130\">",
"      - Cancer and cancer treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2083648074\">",
"      Lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2083648067\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802872638\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802872645\">",
"      - Inflammatory arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802872652\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H384249139\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H384249166\">",
"      - American Physical Therapy Association (APTA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802874472\">",
"      - National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H802880404\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802880717\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802880725\">",
"      Physical exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H857615700\">",
"      Clinical measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H384249248\">",
"      - Optoelectronic volumetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802881735\">",
"      - Circumferential measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802881756\">",
"      - Water displacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802881837\">",
"      - Bioimpedance spectroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802881770\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H802880411\">",
"      - Lymphoscintigraphy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40511035\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H802874506\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802874560\">",
"      Acute deep venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802874522\">",
"      Post-thrombotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802874575\">",
"      Limb hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802874616\">",
"      Lipedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H802871841\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802871848\">",
"      Skin infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802871855\">",
"      Lymphangiosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H802871877\">",
"      Psychological morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/755|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/19/9525\" title=\"figure 1\">",
"      Anatomy of thoracic duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/59/14262\" title=\"figure 2\">",
"      Home arm volumeter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/755|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/11/12471\" title=\"picture 1\">",
"      Lymphedema stageI AB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/15/29942\" title=\"picture 2\">",
"      Lymphedema stageII AB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/2/3112\" title=\"picture 3\">",
"      Lymphedema stageIII ABC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/2/25646\" title=\"table 1\">",
"      Arm volumeter instructions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2217?source=related_link\">",
"      Capillary malformations (port wine stains): Clinical features, diagnosis, and associated syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29177?source=related_link\">",
"      Operative management of primary and secondary lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1657?source=related_link\">",
"      Pathophysiology and etiology of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/1/24594?source=related_link\">",
"      Patient information: Lymphedema after breast cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23127?source=related_link\">",
"      Post-thrombotic (postphlebitic) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_52_1867="Ddx of brain abscess";
var content_f1_52_1867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of brain abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Epidural and subdural empyema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic dural sinus thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycotic cerebral aneurysms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic cerebral emboli with associated infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute focal necrotizing encephalitis (most commonly due to herpes simplex virus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metastatic or primary brain tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyogenic meningitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1867=[""].join("\n");
var outline_f1_52_1867=null;
var title_f1_52_1868="Clinical features UV";
var content_f1_52_1868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of urticarial vasculitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cutaneous features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Erythematous urticarial papules and plaques (wheals), angioedema, dermographism, annular erythema",
"       </td>",
"       <td>",
"        Musculoskeletal: arthralgia, arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Less common",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Urticarial lesions with residual hyperpigmentation and/or purpura",
"       </td>",
"       <td>",
"        Respiratory: cough, dyspnea, hemoptysis, COPD, asthma, pleural effusion",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal disease: proteinuria,  hematuria, glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal: substernal pain, abdominal pain, nausea, vomiting, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Rare",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Erythema multiforme-like lesions, livedo reticularis, Raynaud's phenomenon, laryngeal edema",
"       </td>",
"       <td>",
"        Cardiac: pericarditis, pericardial effusion, cardiac tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmologic: conjunctivitis, episcleritis, uveitis, geographic serpiginous",
"choroidopathy, visual loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other: fever, splenomegaly, lymphadenopathy, cold sensitivity,",
"reversible tracheal stenosis&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Very rare",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        CNS: pseudotumor cerebri, cranial nerve&nbsp;palsies, aseptic meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous: transverse myelitis, cardiac valve disease, optic atrophy, Jaccoud's syndrome",
"(chronic post-rheumatic fever arthropathy), peripheral neuropathy,",
"pleuritis&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1868=[""].join("\n");
var outline_f1_52_1868=null;
var title_f1_52_1869="Terminology used in LBP";
var content_f1_52_1869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Terminology used in back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       <strong>",
"        Spondylosis:",
"       </strong>",
"       arthritis of the spine. Seen radiographically as disc space narrowing and arthritic changes of the facet joint.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Spondylolisthesis:",
"       </strong>",
"       anterior displacement of a vertebra on the one beneath it. A radiologist determines the degree of slippage upon reviewing spinal x-rays. Slippage is graded I through IV:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Grade I - 1 percent to 25 percent slip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Grade II - 26 percent to 50 percent slip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Grade III - 51 percent to 75 percent slip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Grade IV - 76 percent to 100 percent slip",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Generally, Grade I and Grade II slips do not require surgical treatment and are treated medically. However, Grade III and Grade IV slips, and some milder grade slips, may benefit from surgery if persistent and disabling symptoms are present.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Spondylolysis:",
"       </strong>",
"       a fracture in the pars interarticularis where the vertebral body and the posterior elements, protecting the nerves are joined. In a small percent of the adult population, there is a developmental crack in one of the vertebrae, usually at L5.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Spinal stenosis:",
"       </strong>",
"       local, segmental, or generalized narrowing of the central spinal canal by bone or soft tissue elements, usually bony hypertrophic changes in the facet joints and by thickening of the ligamentum flavum.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Radiculopathy:",
"       </strong>",
"       impairment of a nerve root, usually causing radiating pain, numbness, tingling or muscle weakness that corresponds to a specific nerve root.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Sciatica:",
"       </strong>",
"       pain, numbness, tingling in the distribution of the sciatic nerve, radiating down the posterior or lateral aspect of the leg, usually to the foot or ankle.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Cauda equina syndrome:",
"       </strong>",
"       loss of bowel and bladder control and numbness in the groin and saddle area of the perineum, associated with weakness of the lower extremities. This condition can be caused by abnormal pressure on the bottom-most portion of the spinal canal and spinal nerve roots, related to either bony stenosis or a large herniated disc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Lordosis, kyphosis, scoliosis:",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Kyphotic curves refer to the outward curve of the thoracic spine (at the level of the ribs).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Lordotic curves refer to the inward curve of the lumbar spine (just above the buttocks).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Scoliotic curving is a sideways curvature of the spine and is always abnormal.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A small degree of both kyphotic and lordotic curvature is normal. Too much kyphotic curving causes round shoulders or hunched shoulders (Scheuermann's disease).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Too much lordotic curving is called swayback (lordosis). Lordosis tends to make the buttocks appear more prominent.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Piriformis syndrome:",
"       </strong>",
"       thought to be a condition in which the piriformis muscle compresses or irritates the sciatic nerve. The piriformis muscle is a narrow muscle located in the buttocks. There is debate among the medical community whether this is a discrete condition since it lacks objective diagnostic evidence and therefore cannot be reliably assessed.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_52_1869=[""].join("\n");
var outline_f1_52_1869=null;
var title_f1_52_1870="Contents: Urticaria and angioedema";
var content_f1_52_1870=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Urticaria and angioedema",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Urticaria and angioedema",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Angioedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/37/37465\">",
"           ACE inhibitor-induced angioedema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26824\">",
"           Acquired C1 inhibitor deficiency: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/20/25927\">",
"           Acquired C1 inhibitor deficiency: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15641\">",
"           An overview of angioedema: Clinical features, diagnosis, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19272\">",
"           Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33864\">",
"           Hereditary angioedema: Pathogenesis and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29658\">",
"           Hereditary angioedema: Prevention of attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33657\">",
"           Hereditary angioedema: Treatment of acute attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/61/5080\">",
"           Type III hereditary angioedema",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urticaria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30010\">",
"           Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/7/117\">",
"           Chronic urticaria: Standard management and patient education",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/53/30554\">",
"           Chronic urticaria: Treatment of refractory symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15721\">",
"           Cold urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24666\">",
"           Physical urticarias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C422826CC9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_52_1870=[""].join("\n");
var outline_f1_52_1870=null;
var title_f1_52_1871="Contents: Pediatric procedures";
var content_f1_52_1871=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric procedures",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric procedures",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Airway",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29030\">",
"           Basic airway management in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39337\">",
"           Devices for difficult endotracheal intubation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/61/17367\">",
"           Emergency airway management in children: Unique pediatric considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/45/37593\">",
"           Emergency rescue devices for difficult pediatric airway management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/48/29450\">",
"           Emergent endotracheal intubation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/3/16441\">",
"           Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24026\">",
"           Rapid sequence intubation (RSI) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anesthesia and sedation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23703\">",
"           Digital nerve block",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33689\">",
"           Infiltration of local anesthetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31194\">",
"           Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/47/29432\">",
"           Preparation for pediatric procedural sedation outside of the operating room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/23/43384\">",
"           Procedural sedation in children outside of the operating room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/3/25658\">",
"           Selection of medications for pediatric procedural sedation outside of the operating room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/50/43817\">",
"           Topical anesthetics in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiopulmonary life support",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/17/28948\">",
"           Assessment of perfusion in pediatric resuscitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7864\">",
"           Basic life support in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/49/21272\">",
"           Defibrillation and cardioversion in children (including automated external defibrillation)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40761\">",
"           Intraosseous infusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8057\">",
"           Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/61/2009\">",
"           Arterial puncture and cannulation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/47/3833\">",
"           Principles of ultrasound-guided venous access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8057\">",
"           Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear nose and throat",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28504\">",
"           Diagnosis and management of foreign bodies of the outer ear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17752\">",
"           Diagnosis and management of intranasal foreign bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/58/26536\">",
"           Management of epistaxis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastroenterology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/3/21561\">",
"           Overview of inguinal hernia in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30100\">",
"           Management of zipper injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/48/33543\">",
"           Paraphimosis reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/56/42886\">",
"           Urine collection techniques in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Minor emergency procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6137\">",
"           Assessment and management of auricle (ear) lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/53/12122\">",
"           Assessment and management of facial lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/51/18232\">",
"           Assessment and management of intra-oral lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/29/23000\">",
"           Assessment and management of lip lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/9/30872\">",
"           Assessment and management of scalp lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33124\">",
"           Closure of minor skin wounds with staples",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/7/18553\">",
"           Closure of skin wounds with sutures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16216\">",
"           Digit dislocation reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24309\">",
"           Evaluation and repair of tongue lacerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38564\">",
"           Fish-hook removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/47/13044\">",
"           Hair entrapment removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/23/4472\">",
"           Management of fingertip injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30100\">",
"           Management of zipper injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/51/32567\">",
"           Minor wound preparation and irrigation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38532\">",
"           Radial head subluxation (nursemaid's elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/49/8981\">",
"           Ring removal techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/8/9351\">",
"           Subungual hematoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41478\">",
"           Superficial wound repair with tissue adhesives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5865\">",
"           Technique of incision and drainage for skin abscess",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Musculoskeletal",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/40/31368\">",
"           Closed reduction and casting of distal forearm fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/9/38038\">",
"           Knee (tibiofemoral) dislocation and reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24581\">",
"           Patellar dislocations in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6854\">",
"           Pediatric cervical spine immobilization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38532\">",
"           Radial head subluxation (nursemaid's elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26340\">",
"           Reduction of temporomandibular joint (TMJ) dislocation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15208\">",
"           Splinting of musculoskeletal injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/8/9351\">",
"           Subungual hematoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/1/25625\">",
"           Lumbar puncture: Indications, contraindications, technique, and complications in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6854\">",
"           Pediatric cervical spine immobilization",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44486\">",
"           Slit lamp examination",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/61/2009\">",
"           Arterial puncture and cannulation in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma life support",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6854\">",
"           Pediatric cervical spine immobilization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/12/1226\">",
"           Placement and management of thoracostomy tubes",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-A3A19E0D5A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f1_52_1871=[""].join("\n");
var outline_f1_52_1871=null;
